Targeting a Uniquely Nonspecific Prenyl Synthase with Bisphosphonates to Combat Cryptosporidiosis

Chemistry and Biology

Volumn 15, Issue 12, 2008, Pages 1296-1306

  Artz, Jennifer D ^a   Dunford, James E ^b   Arrowood, Michael J ^c   Dong, Aiping ^a   Chruszcz, Maksymilian ^d,e   Kavanagh, Kathryn L ^b   Minor, Wladek ^d,e   Russell, R Graham G ^b   Ebetino, F Hal ^f   Oppermann, Udo ^b   Hui, Raymond ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e Midwest Center for Structural Genomics

^f PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

CHEMBIO; MICROBIO

Indexed keywords

ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; DIMETHYLALLYLTRANSFERASE;

ANIMAL; ARTICLE; CATTLE; CELL CULTURE; CHEMICAL STRUCTURE; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IC 50; LIQUID CHROMATOGRAPHY; METABOLISM; PROTEIN PRENYLATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTI-INFECTIVE AGENTS; CATTLE; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; CRYSTALLOGRAPHY, X-RAY; DIMETHYLALLYLTRANSTRANSFERASE; DIPHOSPHONATES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN PRENYLATION;

CRYPTOSPORIDIUM; CRYPTOSPORIDIUM PARVUM;

EID: 57649227299     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2008.10.017     Document Type: Article

References (56)

1. Arrowood M.J. In vitro cultivation of Cryptosporidium species. Clin. Microbiol. Rev. 15 (2002) 390-400
2. Arrowood M.J. In Vitro Cultivation. In: Fayer R., and Xiao L. (Eds). Cryptosporidium and Cryptosporidiosis. Second Edition (2007), CRC Press, Boca Raton, FL 499-525
3. Arrowood M.J., and Donaldson K. Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients. J. Eukaryot. Microbiol. 43 (1996) 89S
4. Arrowood M.J., and Sterling C.R. Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients. J. Parasitol. 73 (1987) 314-319
5. Arrowood M.J., Xie L.T., and Hurd M.R. In vitro assays of maduramicin activity against Cryptosporidium parvum. J. Eukaryot. Microbiol. 41 (1994) 23S
6. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., and Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373 (2000) 231-241
7. Berkman D.S., Lescano A.G., Gilman R.H., Lopez S.L., and Black M.M. Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet 359 (2002) 564-571
8. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763
9. Chang T.H., Guo R.T., Ko T.P., Wang A.H.J., and Liang P.H. Crystal structure of type-III geranylgeranyl pyrophosphate synthase from Saccharomyces cerevisiae and the mechanism of product chain length determination. J. Biol. Chem. 281 (2006) 14991-15000
10. Chen A., and Poulter C.D. Purification and characterization of farnesyl diphosphate/geranylgeranyl diphosphate synthase: a thermostable bifunctional enzyme from Methanobacterium thermoautotrophicum. J. Biol. Chem. 268 (1993) 11002-11007
11. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006) 621-681
12. Clastre M., Goubard A., Prel A., Mincheva Z., Viaud-Massuart M.C., Bout D., Rideau M., Velge-Roussel F., and Laurent F. The methylerythritol phosphate pathway for isoprenoid biosynthesis in coccidia: presence and sensitivity to fosmidomycin. Exp. Parasitol. 116 (2007) 375-384
13. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
14. Emsley P., and Cowtan K. COOT: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
15. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., and Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
16. Fisher J.E., Rodan G.A., and Reszka A.A. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141 (2000) 4793-4796
17. Fujii H., Koyama T., and Ogura K. Efficient enzymatic hydrolysis of polyprenyl pyrophosphates. Biochim. Biophys. Acta 712 (1982) 716-718
18. Fujiwara S., Yamanaka A., Hirooka K., Kobayashi A., Imanaka T., and Fukusaki E. Temperature-dependent modulation of farnesyl diphosphate/geranylgeranyl diphosphate synthase from hyperthermophilic archaea. Biochem. Biophys. Res. Commun. 325 (2004) 1066-1074
19. Guo R.T., Cao R., Liang P.H., Ko P.T., Chang T.H., Hudock M.P., Jeng W.Y., Chen C.K., Zhang Y., Song Y., et al. Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc. Natl. Acad. Sci. USA 104 (2007) 10022-10027
20. Guo R.T., Ko T.P., Chen A.P.C., Kuo C.J., Wang A.H.J., and Liang P.H. Crystal structures of undecaprenyl pyrophosphate synthase in complex with magnesium, isopentenyl pyrophosphate, and farnesyl thiopyrophosphate: roles of the metal ion and conserved residues in catalysis. J. Biol. Chem. 280 (2005) 20762-20774
21. Guo R.T., Kuo C.J., Chou C.C., Ko T.P., Shr H.L., Liang P.H., and Wang A.H. Crystal structure of octaprenyl pyrophosphate synthase from hyperthermophilic Thermotoga maritima and mechanism of product chain length determination. J. Biol. Chem. 279 (2004) 4903-4912
22. Guo R.T., Kuo C.J., Ko T.P., Chou C.C., Liang P.H., and Wang A.H. A molecular ruler for chain elongation catalyzed by octaprenyl pyrophosphate synthase and its structure-based engineering to produce unprecedented long chain trans-prenyl products. Biochemistry 43 (2004) 7678-7686
23. Heiges M., Wang H., Robinson E., Aurrecoechea C., Gao X., Kaluskar N., Rhodes P., Wang S., He C.Z., Su Y., et al. CryptoDB: a Cryptosporidium bioinformatics resource update. Nucleic Acids Res. 34 (2006) D419-D422
24. Hosfield D.J., Zhang Y., Dougan D.R., Broun A., Tari L.W., Swanson R.V., and Finn J. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J. Biol. Chem. 279 (2004) 8526-8529
25. Kavanagh K.L., Dunford J.E., Bunkoczi G., Russell R.G.G., and Oppermann U. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J. Biol. Chem. 281 (2006) 22004-22012
26. Kavanagh K.L., Guo K.D., Dunford J.E., Wu X.Q., Knapp S., Ebetino F.H., Rogers M.J., Russell R.G.G., and Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as anti osteoporosis drugs. Proc. Natl. Acad. Sci. USA 103 (2006) 7829-7834
27. Kloer D.P., Welsch R., Beyer P., and Schulz G.E. Structure and reaction geometry of geranylgeranyl diphosphate synthase from Sinapis alba. Biochemistry 45 (2006) 15197-15204
28. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
29. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18 (1996) 75-85
30. Ling Y., Li Z.H., Miranda K., Oldfield E., and Moreno S.N. The farnesyl diphosphate/geranylgeranyl diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates. J. Biol. Chem. 282 (2007) 30804-30816
31. Ling Y., Sahota G., Odeh S., Chan J.M.W., Araujo F.G., Moreno S.N.J., and Oldfield E. Bisphosphonate inhibitors of Toxoplasma gondii growth: in vitro, QSAR, and in vivo investigations. J. Med. Chem. 48 (2005) 3130-3140
32. Liu C.I., Liu G.Y., Song Y., Yin F., Hensler M.E., Jeng W.Y., Nizet V., Wang A.H., and Oldfield E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319 (2008) 1391-1394
33. Lovell S.C., Davis I.W., Arendall III W.B., de Bakker P.I., Word J.M., Prisant M.G., Richardson J.S., and Richardson D.C. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 50 (2003) 437-450
34. Martin M.B., Grimley J.S., Lewis J.C., Heath III H.T., Bailey B.N., Kendrick H., Yardley V., Caldera A., Lira R., Urbina J.A., et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44 (2001) 909-916
35. Mead J.R. Cryptosporidiosis and the challenges of chemotherapy. Drug Resist. Updat. 5 (2002) 47-57
36. Moreno B., Bailey B.N., Luo S., Martin M.B., Kuhlenschmidt M., Moreno S.N., Docampo R., and Oldfield E. (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. Biochem. Biophys. Res. Commun. 284 (2001) 632-637
37. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
38. Ohnuma S., Hirooka K., Hemmi H., Ishida C., Ohto C., and Nishino T. Conversion of product specificity of archaebacterial geranylgeranyl-diphosphate synthase - Identification of essential amino acid residues for chain length determination of prenyltransferase reaction. J. Biol. Chem. 271 (1996) 18831-18837
39. Ohnuma S., Nakazawa T., Hemmi H., Hallberg A.M., Koyama T., Ogura K., and Nishino T. Conversion from farnesyl diphosphate synthase to geranylgeranyl diphosphate synthase by random chemical mutagenesis. J. Biol. Chem. 271 (1996) 10087-10095
40. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. C.W., and Sweet R.M. (Eds). Methods in Enzymology, Volume 276: Macromolecular Crystallography, Part A (1997), Academic Press, New York 307-326
41. Perkins M.E., Wu T.W., and Le Blancq S.M. Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum. Antimicrob. Agents Chemother. 42 (1998) 843-848
42. Reed B.C., and Rilling H.C. Crystallization and Partial Characterization of Prenyltransferase from Avian Liver. Biochemistry 14 (1975) 50-54
43. Ricci K.A., Girosi F., Tarr P.I., Lim Y.W., Mason C., Miller M., Hughes J., von Seidlein L., Agosti J.M., and Guerrant R.L. Reducing stunting among children: the potential contribution of diagnostics. Nature 444 Suppl 1 (2006) 29-38
44. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., and Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
45. Rondeau J.M., Bitsch F., Bourgier E., Geiser M., Hemmig R., Kroemer M., Lehmann S., Ramage P., Rieffel S., Strauss A., et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem 1 (2006) 267-273
46. Sanz-Rodriguez C.E., Concepcion J.L., Pekerar S., Oldfield E., and Urbina J.A. Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J. Biol. Chem. 282 (2007) 12377-12387
47. Savioli L., Smith H., and Thompson A. Giardia and Cryptosporidium join the "Neglected Diseases Initiative". Trends Parasitol. 22 (2006) 203-208
48. Smith H.V., and Corcoran G.D. New drugs and treatment for cryptosporidiosis. Curr. Opin. Infect. Dis. 17 (2004) 557-564
49. Tachibana A., Yano Y., Otani S., Nomura N., Sako Y., and Taniguchi M. Novel prenyltransferase gene encoding farnesylgeranyl diphosphate synthase from a hyperthermophilic archaeon, Aeropyrum pernix: molecularevolution with alteration in product specificity. Eur. J. Biochem. 267 (2000) 321-328
50. Tarshis L.C., Proteau P.J., Kellogg B.A., Sacchettini J.C., and Poulter C.D. Regulation of product chain length by isoprenyl diphosphate synthases. Proc. Natl. Acad. Sci. USA 93 (1996) 15018-15023
51. Tarshis L.C., Yan M.J., Poulter C.D., and Sacchettini J.C. Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-Angstrom resolution. Biochemistry 33 (1994) 10871-10877
52. Terwilliger T.C. Automated structure solution, density modification and model building. Acta Crystallogr. D Biol. Crystallogr. 58 (2002) 1937-1940
53. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30 (1997) 1022-1025
54. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun. 255 (1999) 491-494
55. Vedadi M., Lew J., Artz J., Amani M., Zhao Y., Dong A., Wasney G.A., Gao M., Hills T., Brokx S., et al. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol. Biochem. Parasitol. 151 (2007) 100-110
56. Yeates T.O. Detecting and overcoming crystal twinning. In: Carter Jr. C.W., and Sweet R.M. (Eds). Methods in Enzymology, Volume 276: Macromolecular Crystallography, Part A (1997), Academic Press, New York 344-358